3 ms·

Beware surrogates. An apropos bit of news from a few days ago: http://www.nytimes.com/2016/04/04/health/dashing-hopes-study-shows-cholesterol-drug-has-no-benefi

by aab0 11y ago

Beware surrogates. An apropos bit of news from a few days ago: http://www.nytimes.com/2016/04/04/health/dashing-hopes-study-shows-cholesterol-drug-has-no-benefits.html http://www.nytimes.com/2016/04/04/health/dashing-hopes-study... http://blogs.sciencemag.org/pipeline/archives/2016/04/04/cetp-finally-heads-to-the-trash-heap http://blogs.sciencemag.org/pipeline/archives/2016/04/04/cet... Cyclodextrin may be useful for Niemann-Pick disease, where the cholesterol itself is the immediate proximate cause of the problem, but if it's already clinically-approved and has been used, where are the heart attack correlations?

sndean 11y ago
> but if it's already clinically-approved and has been used, where are the heart attack correlations? This is what I'd like to know. I'm not a formulation chemist, but we should see differing outcomes related to different formulations. Maybe someone switched to PEG and saw worse outcomes for this reason? I'd also be interested to see what happens with different substitutions on CD.
mathgeek 11y ago
> but if it's already clinically-approved and has been used, where are the heart attack correlations? I read is as being used currently, but the "breakthrough" being administration through IV. I'm not sure if that's correct, was just my interpretation.